FDA approves panobinostat as a treatment for myeloma

The US Food and Drug Administration (FDA) has approved the use of panobinostat for relapsed myeloma patients who have received at least two prior lines of treatment, including VelcadeĀ®Ā and an immunomodulatory drug, making it the first histone deacetylase (HDAC) inhibitor to be approved for myeloma. Based on the overall results of the Phase III PANORAMA-1…

Details